MindMaze, a Lausanne, Switzerland, London, UK- and Baltimore, MD-based digital neurotherapeutics solutions provider, raised $105M in funding.
The round was led by Concord Health Partners, AlbaCore Capital Group and Hambro Perks.
The company intends to use the funds to accelerate its global commercial growth plans, charge ongoing R&D and consolidate the clinical development pipeline of its digital therapeutic solutions for a wide spectrum of neurological diseases.
Led by Tej Tadi, Founder and CEO, MindMaze focuses on advancing digital neuro-therapeutics (DTx) solutions with to accelerate the brain’s ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating a platform for brain health and recovery and unique digital therapeutic interventions.
MindMaze is ISO 13485 certified and its product portfolio has received three FDA clearances and four CE marks across multiple clinical indications. Operating in more than twenty countries, the company delivers digital assessments and therapeutics over the full continuum of care for thousands of patients suffering from neurological conditions. MindMaze is advancing commercialization in the US by expanding its team and footprint in neurorehabilitation centers, and recently received Current Procedural Terminology (CPT®)1 Category III codes for asynchronous care.